ESCAPHARM
ActiveSummary
ESCAPHARM has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €821,186 and a net result of €119,392. Equity is growing by about 16% per year across the filed financial years. Its solvency ranks better than 70% of 12,464 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
13-08
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format · 13 days late
2025
31-12
Financial
Highest result from 2018 to 2025net €119,392 ▲13.6%
Operating result €207,711, net result €119,392, both a record.
22-08
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format · 22 days late
2024
22-08
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format · 22 days late
2023
24-08
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format · 24 days late
2022
31-12
Financial
Equity above €500,000equity €536,755 ▲17.4%
A profit in every financial year since 2018 builds equity to €536,755.
25-08
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format · 25 days late
2021
28-06
NBB filing
Annual accounts filed
financial year 2020 · abbreviated format
2020
24-08
NBB filing
Annual accounts filed
financial year 2019 · abbreviated format · 24 days late
2019
27-06
NBB filing
Annual accounts filed
financial year 2018 · abbreviated format
2018
02-07
NBB filing
Annual accounts filed
financial year 2017 · abbreviated format
2017
16-08
NBB filing
Annual accounts filed
financial year 2016 · abbreviated format · 16 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 17 annual accounts filed, the latest 10 are here; all 17 are under Financials.
0 of 3 deeds read
About the unread acts
We know of 3 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.